These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34830962)

  • 1. Metabolic Plasticity in Melanoma Progression and Response to Oncogene Targeted Therapies.
    Alkaraki A; McArthur GA; Sheppard KE; Smith LK
    Cancers (Basel); 2021 Nov; 13(22):. PubMed ID: 34830962
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-genetic mechanisms of therapeutic resistance in cancer.
    Marine JC; Dawson SJ; Dawson MA
    Nat Rev Cancer; 2020 Dec; 20(12):743-756. PubMed ID: 33033407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dissecting Mechanisms of Melanoma Resistance to BRAF and MEK Inhibitors Revealed Genetic and Non-Genetic Patient- and Drug-Specific Alterations and Remarkable Phenotypic Plasticity.
    Hartman ML; Sztiller-Sikorska M; Gajos-Michniewicz A; Czyz M
    Cells; 2020 Jan; 9(1):. PubMed ID: 31936151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bad Neighborhood: Fibrotic Stroma as a New Player in Melanoma Resistance to Targeted Therapies.
    Diazzi S; Tartare-Deckert S; Deckert M
    Cancers (Basel); 2020 May; 12(6):. PubMed ID: 32466585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The "ART" of Epigenetics in Melanoma: From histone "Alterations, to Resistance and Therapies".
    Strub T; Ballotti R; Bertolotto C
    Theranostics; 2020; 10(4):1777-1797. PubMed ID: 32042336
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resistance mechanisms to targeted therapy in BRAF-mutant melanoma - A mini review.
    Tangella LP; Clark ME; Gray ES
    Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129736. PubMed ID: 32956754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The great escape: tumour cell plasticity in resistance to targeted therapy.
    Boumahdi S; de Sauvage FJ
    Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor cell-intrinsic phenotypic plasticity facilitates adaptive cellular reprogramming driving acquired drug resistance.
    Hammerlindl H; Schaider H
    J Cell Commun Signal; 2018 Mar; 12(1):133-141. PubMed ID: 29192388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic flexibility in melanoma: A potential therapeutic target.
    Ruocco MR; Avagliano A; Granato G; Vigliar E; Masone S; Montagnani S; Arcucci A
    Semin Cancer Biol; 2019 Dec; 59():187-207. PubMed ID: 31362075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heterogeneity of Melanoma with Stem Cell Properties.
    Seftor EA; Margaryan NV; Seftor REB; Hendrix MJC
    Adv Exp Med Biol; 2019; 1139():105-114. PubMed ID: 31134497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Mechanisms of Resistance to MEK Inhibitors in Melanoma Revealed by Intravital Imaging.
    Brighton HE; Angus SP; Bo T; Roques J; Tagliatela AC; Darr DB; Karagoz K; Sciaky N; Gatza ML; Sharpless NE; Johnson GL; Bear JE
    Cancer Res; 2018 Jan; 78(2):542-557. PubMed ID: 29180473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Neural Crest Transcription Factors Contribute to Melanoma Heterogeneity, Cellular Plasticity, and Treatment Resistance.
    Wessely A; Steeb T; Berking C; Heppt MV
    Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34071193
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overexpression of the human antigen R suppresses the immediate paradoxical proliferation of melanoma cell subpopulations in response to suboptimal BRAF inhibition.
    Fernandez M; Sutterlüty-Fall H; Schwärzler C; Lemeille S; Boehncke WH; Merat R
    Cancer Med; 2017 Jul; 6(7):1652-1664. PubMed ID: 28573821
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy.
    Huang F; Santinon F; Flores González RE; Del Rincón SV
    Front Oncol; 2021; 11():756001. PubMed ID: 34604096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.
    Roesch A; Paschen A; Landsberg J; Helfrich I; Becker JC; Schadendorf D
    Eur J Cancer; 2016 May; 59():109-112. PubMed ID: 27023049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin.
    Ruggiero CF; Malpicci D; Fattore L; Madonna G; Vanella V; Mallardo D; Liguoro D; Salvati V; Capone M; Bedogni B; Ascierto PA; Mancini R; Ciliberto G
    Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31557826
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular Reprogramming-A Model for Melanoma Cellular Plasticity.
    Granados K; Poelchen J; Novak D; Utikal J
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33167306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-induced expression of the RNA-binding protein HuR attenuates the adaptive response to BRAF inhibition in melanoma.
    Merat R; Bugi-Marteyn A; Wrobel LJ; Py C; Daali Y; Schwärzler C; Liaudet N
    Biochem Biophys Res Commun; 2019 Sep; 517(2):181-187. PubMed ID: 31279529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic progression of malignant melanoma.
    Tímár J; Vizkeleti L; Doma V; Barbai T; Rásó E
    Cancer Metastasis Rev; 2016 Mar; 35(1):93-107. PubMed ID: 26970965
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.